We will be hosting our next Investor Forum at Fasken Martineau, on the evening of Wednesday 11th June. You are invited to attend and meet the senior management of Tristel, Regenersis, and Sinclair IS Pharma.
Tristel (TSTL)
On the back of April's upgrade to market expectations, Tristel are riding high. Focused on infection, hygiene and contamination control products, and with their own patented chlorine dioxide chemistry, their products are in use in c.400 hospitals. The strong recurring nature of revenues gives confidence that the strong performance to date can continue.
CEO, Paul Swinney and CFO, Liz Dixon, will be presenting the case for continued growth.
Regenersis (RGS)
Regenersis was already the EMEA's leader for the repair and refurbishment of electronic devices, but it has also recently entered the exciting 'data erasure' market. That was achieved by the purchase of Finnish cyber expert, Blancco, helped by a £100m equity placing.
Jog Dhody, CFO, plans to explain the opportunities ahead for the Group.
Sinclair IS Pharma (SPH)
Sinclair IS is an international specialty pharmaceutical company centred on Dermatology, in particular - Aesthetics, Wound care, and Skin Care. Under a dynamic management team it has successfully completed a series of significant and earnings enhancing product acquisitions over the last 12 months: it now owns a leading product portfolio in their chosen and rapidly growing products' market.
Chris Spooner, CEO, will update our audience.
Venue: Fasken Martineau, 17 Hanover Square, London, W1S 1HU
Time: 5.00pm for 5.30pm start, 35 mins for each company to present and answer questions, then drinks and canapés to follow at 7.15pm.
Date: Wednesday 11th of June
